In the NOAH clinical trial, trastuzumab treatment for locally advanced breast cancer was associated with increased complete and overall response rate and improved event-free survival. The ability to identify this advantage in a relatively smaller number of patients (compared with adjuvant therapy trials) suggests that the neoadjuvant setting might serve to inform the design of adjuvant trials and indicate appropriate off-study adjuvant therapy.
- Heather L. McArthur
- Clifford A. Hudis
